Table 4 Impact of co-trimoxazole prophylaxis on mortality among predominately adult patients with HIV-associated tuberculosis (TB)
From: Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review
Study | Year of publication | Study design | Country | Level of bacterial resistance to co-trimoxazole | No. of study participants | Mortality reduction |
|---|---|---|---|---|---|---|
Wiktor et al. [40] | 1999 | Randomized controlled trial | Cote D’Ivoire | Low | 771 | 46% |
Zachariah et al. [41] | 2003 | Cohort study (‘before’ and ‘after’ study with historical controls) | Malawi (north) | High | 1,986 | 19% |
Mwaungulu et al. [42] | 2004 | Cohort study (‘before’ and ‘after’ study with historical controls) | Malawi (south) | High | 717 | 22% |
Grimwade et al. [43] | 2005 | Cohort study (‘before’ and ‘after’ study with historical controls) | South Africa | High | 3,325 | 29% |
Nunn et al. [44] | 2008 | Randomized controlled trial | Zambia | High | 1,003 | 21% |